zynlonta
(loncastuximab tesirine)ADC Therapeutics America, Inc.
Usage: ZYNLONTA is indicated for adult patients with relapsed or refractory large B-cell lymphoma following two or more systemic therapies, including diffuse large B-cell lymphoma, high-grade B-cell lymphoma, and variants. Approval is based on overall response rates, with continued approval dependent on further confirmation of clinical benefit.